Author details

Full Name

Louis M Staudt

Affiliation

National Cancer Institute, National Institutes of Health

ORCID

Career Start Year

1983

Papers

352

H Index

131

Expertise

CM4AI Collaborator

Nathan Sheffield (CM4AI)

PMID	Paper Title	Journal Title	Published Year
37267580	The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.	J Clin Oncol	2023
37773045	TLR9 ligand sequestration by chemokine CXCL4 negatively affects central B cell tolerance.	J Exp Med	2023
37339580	Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.	Blood	2023
37141112	Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.	Cancer Discov	2023
37267580	The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.	J Clin Oncol	2023
37495782	Double-headed molecule activates cell-death pathways in cancer cells.	Nature	2023
37773045	TLR9 ligand sequestration by chemokine CXCL4 negatively affects central B cell tolerance.	J Exp Med	2023
37495782	Double-headed molecule activates cell-death pathways in cancer cells.	Nature	2023
37339580	Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.	Blood	2023
37141112	Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.	Cancer Discov	2023
34624079	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.	Blood	2022
35839444	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.	J Clin Oncol	2022
35639959	DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.	Blood	2022
36001803	Genomic profiling for clinical decision making in lymphoid neoplasms.	Blood	2022
35944413	Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative.	Transl Oncol	2022
36129999	Burkitt's Lymphoma.	N Engl J Med	2022
35353559	Structure of S1PR2-heterotrimeric G<sub>13</sub> signaling complex.	Sci Adv	2022
34624079	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.	Blood	2022
35145086	In vivo CRISPR screens reveal a HIF-1Î±-mTOR-network regulates T follicular helper versus Th1 cells.	Nat Commun	2022
34818414	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.	Blood	2022
35353559	Structure of S1PR2-heterotrimeric G<sub>13</sub> signaling complex.	Sci Adv	2022
35839444	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.	J Clin Oncol	2022
35639959	DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.	Blood	2022
36001803	Genomic profiling for clinical decision making in lymphoid neoplasms.	Blood	2022
36129999	Burkitt's Lymphoma.	N Engl J Med	2022
35944413	Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative.	Transl Oncol	2022
35145086	In vivo CRISPR screens reveal a HIF-1Î±-mTOR-network regulates T follicular helper versus Th1 cells.	Nat Commun	2022
34818414	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.	Blood	2022
32339229	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.	J Natl Cancer Inst	2021
32339229	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.	J Natl Cancer Inst	2021
33856277	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.	Leuk Lymphoma	2021
33798439	The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.	Cell	2021
33691108	Most non-canonical proteins uniquely populate the proteome or immunopeptidome.	Cell Rep	2021
34007079	Author Correction: The NCI Genomic Data Commons.	Nat Genet	2021
33951889	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	Haematologica	2021
33619384	The NCI Genomic Data Commons.	Nat Genet	2021
33942292	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOPÂ Â±Â ibrutinib.	Br J Haematol	2021
33619257	Uniform genomic data analysis in the NCI Genomic Data Commons.	Nat Commun	2021
33046520	A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.	Clin Cancer Res	2021
33271120	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.	Immunity	2021
33217343	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.	Cancer Cell	2021
34739844	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	Cancer Cell	2021
34625792	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.	Blood Adv	2021
34504346	Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.	Nat Biotechnol	2021
34778802	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.	Blood Cancer Discov	2021
34424958	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.	Blood	2021
33619384	The NCI Genomic Data Commons.	Nat Genet	2021
33619257	Uniform genomic data analysis in the NCI Genomic Data Commons.	Nat Commun	2021
33691108	Most non-canonical proteins uniquely populate the proteome or immunopeptidome.	Cell Rep	2021
33856277	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.	Leuk Lymphoma	2021

1 - 50 of 704

Zhengming Chen

Weill Cornell Medicine and New York Presbyterian Hospital

Career Start Year 2013

Number of shared co-authors 4

Alexandre Rouette

Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine

Career Start Year 2012

Number of shared co-authors 4

Xiaoqiong Wang

The University of Texas MD Anderson Cancer Center

Career Start Year 2011

Number of shared co-authors 0

Stuart J Blakemore

Center for Molecular Medicine Cologne (CMMC), University of Cologne

Career Start Year 2010

Number of shared co-authors 5

Ganiraju C Manyam

the University of Texas MD Anderson Cancer Center

Career Start Year 2009

Number of shared co-authors 4

Anagha Deshpande

Sanford Burnham Prebys Medical Discovery Institute

Career Start Year 2009

Number of shared co-authors 0

Benjamin G Barwick

Emory University School of Medicine

Career Start Year 2009

Number of shared co-authors 3

Camille Lobry

INSERM U1170, Universite Paris Saclay

Career Start Year 2007

Number of shared co-authors 5

Maggie Cam

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 2005

Number of shared co-authors 9

Alexey V Danilov

City of Hope National Medical Center

Career Start Year 2005

Number of shared co-authors 5

Andrew V Kossenkov

The Wistar Institute

Career Start Year 2003

Number of shared co-authors 4

Yuelin J Zhu

National Cancer Institute, National Institutes of Health

Career Start Year 2002

Number of shared co-authors 14

Jacqueline E Payton

Washington University School of Medicine.

Career Start Year 2001

Number of shared co-authors 9

Trang Le

KTH - Royal Institute of Technology

Career Start Year 2000

Number of shared co-authors 1

Andrew J Gentles

Stanford Center for Biomedical Informatics Research, Stanford University

Career Start Year 1999

Number of shared co-authors 12

Katia Basso

Institute for Cancer Genetics, Columbia University

Career Start Year 1999

Number of shared co-authors 3

Lianbo Yu

The Ohio State University

Career Start Year 1997

Number of shared co-authors 3

Robert L Walker

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 1997

Number of shared co-authors 25

Eric Tse

School of Clinical Medicine, University of Hong Kong

Career Start Year 1997

Number of shared co-authors 1

Francisco Vega

The University of Texas MD Anderson Cancer Center

Career Start Year 1996

Number of shared co-authors 23

Ute Fischer

Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf

Career Start Year 1992

Number of shared co-authors 0

Wenbin Wei

Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield

Career Start Year 1991

Number of shared co-authors 1

Ricky W Johnstone

The University of Melbourne

Career Start Year 1990

Number of shared co-authors 7

Todd R Golub

Broad Institute of MIT and Harvard

Career Start Year 1989

Number of shared co-authors 20

Geoffrey Neale

St. Jude Children's Research Hospital

Career Start Year 1989

Number of shared co-authors 9

David M Dorfman

Brigham and Women's Hospital and Harvard Medical School

Career Start Year 1982

Number of shared co-authors 6

Stephen E Kurtz

Knight Cancer Institute, Oregon Health and Science University

Career Start Year 1979

Number of shared co-authors 4

Brian Van Ness

University of Minnesota

Career Start Year 1978

Number of shared co-authors 5

Louise C Showe

The Wistar Institute

Career Start Year 1975

Number of shared co-authors 4

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Career Start Year 1974

Number of shared co-authors 54

row(s) 1 - 30 of 30